Propagenix Revenue and Competitors

Propagenix is an R&D-stage cell therapy company engaged in the development and commercialization of technology which initially originated from the laboratory of Dr. Richard Schlegel of Georgetown University. The company was founded in 2014 and is located in the I-270 corridor of Montgomery County, Maryland. The company is dedicated to continuing to develop Propagenix technology for a wide range of applications in basic and translational biomedical research. Our vision is to enable the creation of new and more effective drugs, personalized diagnostics and cell therapies that will enhance human healthcare. The team has created a culture that places high value and thrives on scientific excellence, innovation, open and honest communication, a collaborative attitude, and a fast-paced work environment Our driving mission at Propagenix is to create innovative cellular technologies that enable the production and delivery of the next generation of tissue therapeutics. Our particular focus is to provide best-in-class and proprietary cell bioproduction platforms for biopharma companies working on regenerative medicine involving epithelial barrier tissues. Our commitment to this focus is fueled by the needs of patients who suffer from the many varied diseases involving epithelial barrier tissue dysfunction and injury. We currently focus on the expansion and differentiation of tissues from two of the most critical organs of the body—the skin and the airway. We are preparing bilayered autologous skin constructs that can be transplanted onto patients with inherited skin diseases as well as for repair of skin that has been injured or has chronic wounds. Cells lining the airway represent the second current focus area. They can be damaged or destroyed by infection, disease or injury. We are endeavoring to provide novel technical solutions for these significant healthcare problems.